

## Multiple Regions of Harvey Sarcoma Virus RNA Can Dimerize In Vitro

YA-XIONG FENG,<sup>1</sup> WILLIAM FU,<sup>1</sup> AREND JAN WINTER,<sup>2</sup> JUDITH G. LEVIN,<sup>3</sup> AND ALAN REIN<sup>1\*</sup>

*Laboratory of Molecular Virology and Carcinogenesis, ABL-Basic Research Program, NCI-Frederick Cancer Research and Development Center, Frederick, Maryland 21702-1201<sup>1</sup>; UPR 9002 du Centre National de la Recherche Scientifique, Institut de Biologie Moléculaire et Cellulaire, 67084 Strasbourg cedex, France<sup>2</sup>; and Laboratory of Molecular Genetics, National Institute of Child Health and Human Development, Bethesda, Maryland 20892<sup>3</sup>*

Received 15 September 1994/Accepted 10 January 1995

**Retroviruses contain a dimeric RNA consisting of two identical molecules of plus-strand genomic RNA. The structure of the linkage between the two monomers is not known, but they are believed to be joined near their 5' ends. Darlix and coworkers have reported that transcripts of retroviral RNA sequences can dimerize spontaneously in vitro (see, for example, E. Bieth, C. Gabus, and J. L. Darlix, *Nucleic Acids Res.* 18:119–127, 1990). As one approach to identification of sequences which might participate in the linkage, we have mapped sequences derived from the 5' 378 bases of Harvey sarcoma virus (HaSV) RNA which can dimerize in vitro. We found that at least three distinct regions, consisting of nucleotides 37 to 229, 205 to 272, and 271 to 378, can form these dimers. Two of these regions contain nucleotides 205 to 226; computer analysis suggests that this region can form a stem-loop with an inverted repeat in the loop. We propose that this hypothetical structure is involved in dimer formation by these two transcripts. We also compared the thermal stabilities of each of these dimers with that of HaSV viral RNA. Dimers of nucleotides 37 to 229 and 205 to 272 both exhibited melting temperatures near that of viral RNA, while dimers of nucleotides 271 to 378 are quite unstable. We also found that dimers of nucleotides 37 to 378 formed at 37°C are less thermostable than dimers of the same RNA formed at 55°C. It seems possible that bases from all of these regions participate in the dimer linkage present in viral RNA.**

The genomic RNA in a retrovirus particle is dimeric. Two molecules of plus-strand genomic RNA are joined together in a noncovalent linkage; the bonds in the dimeric structure are presumably hydrogen bonds and/or other weak bonds, since the dimer is dissociated into monomers under relatively mild conditions (for a review, see reference 4).

It has been proposed (5, 8, 9) that the dimeric structure is a prerequisite for encapsidation of genomic RNA. Obviously, precise knowledge of the nature of this structure would be of great importance. However, this is an extremely challenging problem, given the large size of retroviral genomic RNAs and the low amounts of virus released by virus-producing cells.

Darlix and coworkers have recently made the important finding that relatively short RNA molecules containing retroviral sequences can dimerize in vitro (e.g., see references 3, 5, and 16). This discovery appears to offer the prospect of major new insights into the dimeric structure, since (i) analysis of structures present in shorter molecules is far simpler than analysis of full-length viral RNA; (ii) synthetic transcripts can easily be produced in much larger amounts than are available from standard virus preparations; and (iii) the sequences in the transcripts can readily be altered by deletion and mutation, so that sequence requirements for dimer formation can be determined easily.

Taking advantage of these possibilities, Darlix and others have shown that the retroviral sequences capable of dimerization in vitro are, in general, near the 5' end of the viral genome

(3, 5, 16); this is the region believed to be involved in the dimer structure present in virion RNA, and it is also known to be required for RNA encapsidation (4, 13, 17). Marquet et al. have also reported that dimerization is a specific property of plus-strand transcripts of retroviral sequences, since the complementary RNAs generally do not dimerize in vitro (14). Finally, the thermal stability of these dimers formed in vitro (IVD) is, at least in some cases, similar to that of the dimers found in virions (e.g., see reference 18).

The present report describes experiments mapping retroviral sequences required for dimerization in vitro. These experiments used Harvey sarcoma virus (HaSV); the genomic RNA of this virus does not encode viral proteins but is efficiently encapsidated by proteins of the mammalian type C viruses. Its sequence is nearly identical to that of Moloney murine leukemia virus (Mo-MuLV) for the 5' 206 nucleotides but is quite different 3' of this position (20). While this work was in progress, a report identifying an HaSV sequence capable of dimerization in vitro appeared (23). Our results are consistent with these previously published results but show that the situation is unexpectedly complex: at least two distinct, nonoverlapping regions within the 5' 378 nucleotides are independently capable of dimerization in vitro. At present, we are unable to say which, if any, of the dimeric structures formed by the transcripts in vitro corresponds to the structure actually present in HaSV virion RNA. However, the results raise the possibility that several regions of the genome are involved in the structure of viral RNA.

### MATERIALS AND METHODS

**Molecular clones.** A molecular clone containing HaSV proviral sequences was originally obtained from Douglas Lowy (National Cancer Institute, Bethesda,

\* Corresponding author. Mailing address: ABL-Basic Research Program, NCI-Frederick Cancer Research and Development Center, P.O. Box B, Frederick, MD 21702-1201. Phone: (301) 846-1361. Fax: (301) 846-1666. Electronic mail address: rein@fcrfv1.ncifcrf.gov.




FIG. 1. Dimer formation by RNAs consisting of nucleotides 37 to 378 and 271 to 378. RNAs consisting of nucleotides 37 to 378 (A) and of nucleotides 271 to 378 and 205 to 262 (B) were tested for their ability to form dimers as described in the text. (A) Lanes 1 and 2, 37-to-378 RNA. (B) Lanes 1 and 2, 271-to-378 RNA; lanes 3 and 4, 205-to-262 RNA. Lanes 2 in panel A and 2 and 4 in panel B were incubated in buffer D at 37°C to allow dimer formation as described in Materials and Methods. Note that some dimer is formed even without this incubation (lanes 1 in both panels). D, dimer; M, monomer.

Md.) (27). Sequences between the *KpnI* site at nucleotide 37 and the *BamHI* site at nucleotide 378 (20) were cloned into a synthetic polylinker downstream of an SP6 promoter sequence, in a plasmid vector originally derived from pCMVneo (12); details of this construction are available on request.

Subclones were made in the same plasmid vector by digestion with restriction enzymes, by PCR, or by direct insertion of synthetic oligonucleotides. Each clone made by PCR or by direct insertion was sequenced; in each case, the sequence agreed with the known HaSV sequence (20). The clones analyzed in the present study contained the following stretches of HaSV sequence: nucleotides 37 to 378, 37 to 229, 37 to 210, 118 to 312, 205 to 272, 209 to 272, 205 to 262, and 271 to 378.

**RNA synthesis.** Plasmid DNA was purified by buoyant density centrifugation in CsCl-ethidium bromide gradients. It was linearized by restriction enzyme digestion and transcribed by use of SP6 RNA polymerase (Promega Corp., Madison, Wis.) in the presence of RNasin (Promega). After transcription, the DNA template was digested with DNase (Promega) and the RNA was extracted with phenol-chloroform and precipitated with ethanol. The precipitated RNA was redissolved in RNase-free water (Promega) and purified through a Sephadex G-25 spun column (Boehringer Mannheim, Indianapolis, Ind.). The purity of the RNA was examined by electrophoresis in 2.5% Metaphor (FME, Rockland, Maine) in 50 mM Tris-borate (pH 8.0)–1 mM EDTA followed by staining with ethidium bromide.

**Dimerization conditions.** Conditions for dimerization of RNA were essentially those described by Roy et al. (18). RNA was diluted to 0.5 to 1.0  $\mu\text{g}/10\ \mu\text{l}$ , denatured at 95°C for 2 min, and placed on ice. A portion (1/10 volume) of 10 $\times$  buffer D was then added (1 $\times$  buffer D is 0.25 M NaCl, 1 mM MgCl<sub>2</sub>, 10 mM Tris [pH 7.0]), and the RNA was incubated at 37°C for 2 h (or, where indicated below, at 55°C for 30 min). The extent of dimerization was determined by electrophoresis in Metaphor as described above. In many cases, dimerization of a transcript was partially completed at the end of the transcription reaction (before incubation in buffer D), but no dimers were seen in the case of negative transcripts.

**Analysis of thermal stability of dimers.** RNA which had been fully dimerized (as determined by agarose gel electrophoresis under native conditions, as described above) was diluted to 10<sup>-7</sup> M and microdialyzed, with a type V6 filter (pore size, 0.025  $\mu\text{m}$ ; Millipore Corp., Bedford, Mass.), for 45 min against buffer A (50 mM NaCl, 10 mM Tris-Cl [pH 7.0], 1 mM EDTA). Aliquots were then removed and incubated for 10 min at temperatures ranging from 37 to 70°C. Another aliquot was incubated for 2 min at 90°C. The RNAs were then analyzed by electrophoresis as described above, to determine the extent of dissociation of the dimer resulting from the incubation at each temperature.

**Analysis of viral RNAs.** Plasmids containing either wild-type or the D32L protease mutant (8) of Mo-MuLV (in a vector derived from pSV2neo [21]) were transfected (10) into NRK rat cells transformed by HaSV (also a gift of Douglas Lowy), and stable transfectants were selected with G418 (Life Technologies Inc., Gaithersburg, Md.). RNA was extracted from viral pellets as described elsewhere (8), and HaSV RNA was analyzed by nondenaturing Northern (RNA) gel analysis (11) with <sup>32</sup>P-labeled pBS9 DNA as a *ras* probe (6). Thermal stability measurements were in buffer A with 1% sodium dodecyl sulfate (SDS), as described elsewhere (8).

## RESULTS

RNAs representing portions of the genomic RNA of HaSV were tested for their ability to form IVD as follows. Segments of cloned HaSV DNA were transcribed with SP6 RNA polymerase, and the resulting RNAs were incubated in buffer D to allow dimer formation, as described in Materials and Methods.




FIG. 2. Transcripts from different regions of the HaSV genome were tested for their ability to dimerize as described in Materials and Methods. +,  $\geq 50\%$  dimerization;  $\pm$ ,  $\sim 20\%$  dimerization; -,  $\leq 10\%$  dimerization; nt, nucleotide(s).

The capability of a relatively large 5' RNA molecule, encoded by the HaSV genome between the *KpnI* site at nucleotide 37 and the *BamHI* site at nucleotide 378, to dimerize in vitro was tested initially. As shown in Fig. 1A, it was found that this RNA dimerizes readily under the standard incubation conditions.

**Partial identification of dimerization sequences.** We then




FIG. 3. Melting profiles of HaSV RNA isolated from virions after rescue of HaSV with either wild-type (A) or PR<sup>-</sup> (B) Mo-MuLV. RNAs extracted from the respective virions were dissolved in buffer A supplemented with 1% SDS at room temperature. Aliquots of the RNAs were heated for 10 min at the indicated temperatures. The RNA samples were analyzed by nondenaturing Northern blotting, with a pBS9 probe to detect the HaSV genome, as described in Materials and Methods. D, dimer; M, monomer.

subdivided this 342-nucleotide region, in an attempt to localize the sequences required for dimerization. Results of all these tests are summarized in Fig. 2. At the 5' end of this region, we found that RNA composed of HaSV nucleotides 37 to 229 can dimerize (see below). In addition, a transcript of the central portion of the region, consisting of nucleotides 118 to 312, could also dimerize. Finally, sequences from the 3' end of the region, i.e., nucleotides 271 to 378, were also capable of dimerization (Fig. 1B), although the dimerization of this transcript was frequently incomplete and, as noted below, these dimers were quite unstable.

The subclones described above were also subdivided further (Fig. 2). Within the 5' region (nucleotides 37 to 229), an RNA consisting of nucleotides 37 to 210 was unable to dimerize *in vitro*.

Within the central region, nucleotides 205 to 272 were capable of dimerization, in agreement with results of Torrent et al. (24). Nucleotides at both ends of this transcript are evidently involved in dimerization, since RNAs composed of nucleotides 209 to 272 (Fig. 2) did not form IVD, while transcripts of nucleotides 205 to 262 formed IVD with very low efficiency (Fig. 1B and 2). The fact that many transcripts fail to dimerize (Fig. 2) demonstrates the specificity of the assay.

**Thermal stability of dimers.** The studies described above showed that the 5' region of HaSV RNA contains at least three stretches capable of dimerization under the incubation conditions used: nucleotides 37 to 229, 205 to 272, and 271 to 378 (Fig. 2). It would be important to know which, if any, of these stretches is involved in the linkage between full-length HaSV genomic RNAs in virions.

One property which can be used to characterize dimeric RNAs is thermal stability. We therefore compared the dissociation temperatures of the dimers formed *in vitro* with that of genomic HaSV RNA, in hopes of identifying an IVD which resembled the dimers present in virions.

We initially determined the dissociation temperatures of HaSV viral RNAs. The helper viruses used were wild-type Mo-MuLV and protease-negative (PR<sup>-</sup>) Mo-MuLV; it was important to test both of these preparations, since the melting temperatures of Mo-MuLV and human immunodeficiency virus type 1 (HIV-1) viral RNAs are affected by PR function (7, 8) and it seemed likely that the same would be true of HaSV RNA. The results of these tests are shown in Fig. 3; it can be seen that the HaSV dimers in both samples dissociated at approximately 60°C.

Melting profiles of selected IVD are shown in Fig. 4. These tests were performed in the same buffer as that used in analysis of viral RNAs except that SDS was not included in the tests on IVD; this buffer (buffer A) is of significantly lower ionic strength than the solutions used for dimer formation *in vitro* and contains EDTA rather than Mg<sup>2+</sup>. Briefly, the results showed that IVD of nucleotides 37 to 229 dissociate between 55 and 65°C (Fig. 4A); dimers of nucleotides 205 to 272 dissociate at 65 to 70°C (Fig. 4B); and dimers of nucleotides 271 to 378 are quite unstable under the conditions of the melting experiments (i.e., in buffer A rather than the dimerization buffer), since they are partially dissociated at 37°C and completely dissociated at 55°C (Fig. 4C).

We also examined the thermal stability of dimers of the entire region under study, i.e., nucleotides 37 to 378. Preliminary experiments suggested that the melting profile of these IVD might depend upon the conditions used for dimerization. To test this possibility directly, we performed the following experiment. RNA consisting of nucleotides 37 to 378 was prepared and divided in two aliquots. One was incubated in dimerization buffer (buffer D) at 37°C, while the other was incubated in the same buffer at 55°C. Dimerization was complete under




FIG. 4. Melting profile of HaSV IVD. After dimerization, RNA was microdialyzed into buffer A and aliquots were incubated for 10 min at the indicated temperatures. The RNAs were then analyzed by agarose gel electrophoresis. (A) 37-to-229 RNA; B, 205-to-272 RNA; C, 271-to-378 RNA. D, dimer; M, monomer.

both conditions. The thermal stabilities of the dimers were then compared. As can be seen (Fig. 5), the dimer which had been formed at 37°C had a very broad (probably biphasic) melting profile: some dimers were dissociated by exposure to 45°C, but dissociation was only complete at a temperature between 70 and 90°C. In contrast, the dimers which had been formed at 55°C exhibited a much sharper melting profile, in which no dissociation was seen until the IVD were incubated at 65°C.

We also tested the possibility that the melting temperatures of other IVD would be dependent on conditions used in dimer formation. However, dimers of nucleotides 37 to 229, 205 to




FIG. 5. Melting profiles of dimeric RNAs of nucleotides 37 to 378. The effects of dimerization temperature upon melting profiles are shown. RNA composed of nucleotides 37 to 378 was incubated in buffer D at either 37 or 55°C. Dimerization was complete at both temperatures. Melting profiles of the dimers were then determined as for Fig. 4. D, dimer; M, monomer.



nucleotides 311 to 415 is not present in full-length viral RNA (7, 15, 19).

The second observation concerning thermal stability of IVD is the existence of two dimeric forms of nucleotides 37 to 378 with different melting profiles. We have recently reported (7, 8) that full-length genomic RNAs of Mo-MuLV, Kirsten sarcoma virus, and HIV-1 can each exist in two alternative forms; however, this has not previously been observed in IVD. Indeed, we could not have predicted that this would be true of such short transcripts. We found (Fig. 5) that annealing at a high temperature (55°C) resulted in a more stable dimer than annealing at a lower temperature (37°C). Presumably, some intramolecular bonds present in monomers incubated at 37°C are broken at 55°C, so that more bases are available for intermolecular interactions at the latter temperature and a more stable dimer is generated.

In authentic viral RNAs, the transition from one form to the other is dependent upon the activity of the viral PR (7, 8). We have suggested (8) that PR cleaves the Gag polyprotein and that one of the cleavage products, the nucleocapsid (NC) protein, binds to the viral RNA and alters the conformation of the dimer. With this hypothesis in mind, we are now investigating the effect of purified NC protein upon IVD of nucleotides 37 to 378 formed at 37°C.

In both Mo-MuLV and HIV-1, the dimeric form found in virus particles containing functional PR is more thermostable than that in PR<sup>-</sup> particles (7, 8). It seems reasonable to suppose that NC in the PR<sup>+</sup> particles catalyzes a transition of the dimer to a more stable, more thermodynamically favored form (26). However, in the present work we were unable to distinguish the dissociation temperatures of HaSV genomic RNAs packaged into virions by wild-type Mo-MuLV proteins from those packaged by PR<sup>-</sup> ones (Fig. 3). Other experiments (not shown) demonstrated that these HaSV RNAs were nevertheless in different conformations, since they exhibited different electrophoretic mobilities in nondenaturing agarose gels. It is, of course, possible that HaSV dimers from wild-type particles are slightly more stable than those from PR<sup>-</sup> particles.

In summary, at least two different regions of HaSV RNA can form IVD. This finding raises the possibility that more than one region contributes to the dimeric structure in the virus particle. Alternatively, some of the structures formed *in vitro* may not exist *in vivo*, as is evidently the case with HIV-1 RNA (7, 15, 19). Ultimately, determining the structure of the RNA in the virus will require direct biochemical analysis. It is likely that IVD will provide useful models for this analysis, since the dimeric structure described for Moloney MuLV IVD (25) is quite similar to that present in the virus (1).

#### ACKNOWLEDGMENTS

We thank Douglas Lowy for reagents, Marilyn Powers for oligonucleotides, Jane Mirro for excellent technical assistance, and Carol Shawver for help with preparation of the manuscript.

This research was sponsored by the National Cancer Institute, DHHS, under contract NO1-CO-74101 with ABL, and supported in part by the National Institutes of Health Intramural AIDS Targeted Antiviral Program.

#### REFERENCES

- Alford, R. L., S. Honda, C. B. Lawrence, and J. W. Belmont. 1991. RNA secondary structure analysis of the packaging signal for Moloney murine leukemia virus. *Virology* **183**:611–619.
- Awang, G., and D. Sen. 1993. Mode of dimerization of HIV-1 genomic RNA. *Biochemistry* **32**:11453–11457.
- Bieth, E., C. Gabus, and J. L. Darlix. 1990. A study of the dimer formation of Rous sarcoma virus RNA and its effect on viral protein synthesis *in vitro*. *Nucleic Acids Res.* **18**:119–127.
- Coffin, J. 1984. Genome structure, p. 261–368. *In* R. Weiss, N. Teich, H. Varmus, and J. Coffin (ed.), *RNA tumor viruses*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
- Darlix, J.-L., C. Gabus, M. T. Nugeyre, F. Clavel, and F. Barré-Sinoussi. 1990. *cis* elements and *trans*-acting factors involved in the RNA dimerization of the human immunodeficiency virus HIV-1. *J. Mol. Biol.* **216**:689–699.
- Ellis, R. W., D. DeFeo, J. M. Maryak, H. A. Young, T. Y. Shih, E. H. Chang, D. R. Lowy, and E. M. Scolnick. 1980. Dual evolutionary origin for the rat genetic sequences of Harvey murine sarcoma virus. *J. Virol.* **36**:408–420.
- Fu, W., R. J. Gorelick, and A. Rein. 1994. Characterization of human immunodeficiency virus type 1 dimeric RNA from wild-type and protease-defective virions. *J. Virol.* **68**:5013–5018.
- Fu, W., and A. Rein. 1993. Maturation of dimeric viral RNA of Moloney murine leukemia virus. *J. Virol.* **67**:5443–5449.
- Gorelick, R. J., S. M. Nigida, Jr., L. O. Arthur, L. E. Henderson, and A. Rein. 1991. Roles of nucleocapsid cysteine arrays in retroviral assembly and replication: possible mechanisms in RNA encapsidation, p. 257–272. *In* A. Kumar (ed.), *Advances in molecular biology and targeted treatment for AIDS*. Plenum Press, New York.
- Graham, F. L., and A. J. van der Eb. 1973. A new technique for the assay of infectivity of human adenovirus 5 DNA. *Virology* **52**:456–467.
- Jaeger, J. A., D. H. Turner, and M. Zuker. 1989. Improved predictions of secondary structures for RNA. *Proc. Natl. Acad. Sci. USA* **86**:7706–7710.
- Khandjian, E. W., and C. Méric. 1986. A procedure for Northern blot analysis of native RNA. *Anal. Biochem.* **159**:227–232.
- Konings, D. A. M., M. A. Nash, J. V. Maizel, and R. B. Arlinghaus. 1992. Novel GACG-hairpin pair motif in the 5' untranslated region of type C retroviruses related to murine leukemia virus. *J. Virol.* **66**:632–640.
- Laughrea, M., and L. Jetté. 1994. A 19-nucleotide sequence upstream of the 5' major splice donor is part of the dimerization domain of human immunodeficiency virus 1 genomic RNA. *Biochemistry* **33**:13464–13474.
- Linial, M. 1987. Creation of a processed pseudogene by retroviral infection. *Cell* **49**:93–102.
- Linial, M. L., and A. D. Miller. 1990. Retroviral RNA packaging: sequence requirements and implications, p. 125–152. *In* R. Swanstrom and P. Vogt (ed.), *Retroviruses. Strategies of replication*. Springer-Verlag, Berlin.
- Marquet, R., F. Baudin, C. Gabus, J.-L. Darlix, M. Mougél, C. Ehresmann, and B. Ehresmann. 1991. Dimerization of human immunodeficiency virus (type 1) RNA: stimulation by cations and possible mechanism. *Nucleic Acids Res.* **19**:2349–2357.
- Marquet, R., J.-C. Paillart, E. Skripkin, C. Ehresmann, and B. Ehresmann. 1994. Dimerization of human immunodeficiency virus type 1 RNA involves sequences located upstream of the splice donor site. *Nucleic Acids Res.* **22**:145–151.
- Prats, A.-C., C. Roy, P. Wang, M. Erard, V. Housset, C. Gabus, C. Paoletti, and J.-L. Darlix. 1990. *cis* elements and *trans*-acting factors involved in dimer formation of murine leukemia virus RNA. *J. Virol.* **64**:774–783.
- Rein, A. 1994. Retroviral RNA packaging: a review. *Arch. Virol.* **9**(Suppl.): 513–522.
- Roy, C., N. Tounekti, M. Mougél, J. L. Darlix, C. Paoletti, C. Ehresmann, B. Ehresmann, and J. Paoletti. 1990. An analytical study of the dimerization of *in vitro* generated RNA of Moloney murine leukemia virus MoMuLV. *Nucleic Acids Res.* **18**:7287–7292.
- Skripkin, E., J.-C. Paillart, R. Marquet, B. Ehresmann, and C. Ehresmann. 1994. Identification of the primary site of the human immunodeficiency virus type 1 RNA dimerization *in vitro*. *Proc. Natl. Acad. Sci. USA* **91**:4945–4949.
- Soeda, E., and S. Yasuda. 1985. Harvey murine sarcoma virus (Ha-MSV) genome, p. 928–939. *In* R. Weiss, N. Teich, H. Varmus, and J. Coffin (ed.), *RNA tumor viruses: molecular biology of tumor viruses*, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
- Southern, P. J., and P. Berg. 1982. Transformation of mammalian cells to antibiotic resistance with a bacterial gene under control of the SV40 early region promoter. *J. Mol. Appl. Genet.* **1**:327–341.
- Sundquist, W. L., and S. Heaphy. 1993. Evidence for interstrand quadruplex formation in the dimerization of human immunodeficiency virus 1 genomic RNA. *Proc. Natl. Acad. Sci. USA* **90**:3393–3397.
- Torrent, C., T. Bordet, and J.-L. Darlix. 1994. Analytical study of rat retrotransposon VL30 RNA dimerization *in vitro* and packaging in murine leukemia virus. *J. Mol. Biol.* **240**:434–444.
- Torrent, C., C. Gabus, and J.-L. Darlix. 1994. A small and efficient dimerization/packaging signal of rat VL30 RNA and its use in murine leukemia virus-VL30-derived vectors for gene transfer. *J. Virol.* **68**:661–667.
- Tounekti, N., M. Mougél, C. Roy, R. Marquet, J.-L. Darlix, J. Paoletti, B. Ehresmann, and C. Ehresmann. 1992. Effect of dimerization on the conformation of the encapsidation Psi domain of Moloney murine leukemia virus RNA. *J. Mol. Biol.* **223**:205–220.
- Tsuchihashi, Z., and P. O. Brown. 1994. DNA strand exchange and selective DNA annealing promoted by the human immunodeficiency virus type 1 nucleocapsid protein. *J. Virol.* **68**:5863–5870.
- Velu, T. J., W. C. Vass, D. R. Lowy, and P. E. Tambourin. 1989. Harvey murine sarcoma virus: influences of coding and noncoding sequences on cell transformation *in vitro* and oncogenicity *in vivo*. *J. Virol.* **63**:1384–1392.